FDA Rejects Proposed Chronic Kidney Disease Indication for Vytorin

? The FDA rejected a new indication??for Merck?s Vytorin and Zetia (ezetimibe plus simvastatin and ezetimibe alone) in chronic kidney disease patients. As a consolation prize, however, the agency approved a new label for the drugs that will incorporate the results of SHARP (Study of Heart and Renal Protection), which found that Vytorin reduced the …

Leave a Reply

Your email address will not be published.

*